CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
Currently, there are limited supplies of the reagents used for HIV-1 Western Blot and HIV-2 EIA test...
CTS Spotlight at 2018 AABB Annual Meeting Sunday, October 14, 2018 at 1:30 PM: Scientific Oral ...
The CTS Medical Advisory Board recently agreed upon a revision to our standard testing algorithm. Th...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
On June 13, 2019, the new CTS Laboratory Information System was successfully implemented in Cha...
CTS Charlotte Lab successfully implemented WNV NAT testing on the Panther Testing Platform on Monday...